A case report on transient cardiomyopathy with cytokine storm in SARS-CoV-2

Abstract

Background Cardiac manifestations during Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) pandemic have included acute coronary syndrome, arrhythmias, myocarditis, and stress cardiomyopathy. However, the combination of cardiomyopathy and negative cardiac biomarkers has not yet been reported. Case summary A 49-year-old man admitted for respiratory failure secondary to SARS-CoV-2 developed new-onset cardiomyopathy with negative cardiac biomarkers. Left ventricular ejection fraction and strain improved 7 days after the initial echocardiogram, after administration of Tocilizumab, coinciding with clinical recovery, and improvement in inflammatory markers. Discussion As experience of cardiovascular manifestations of SARS-CoV-2 increases, more patients will likely present with cardiovascular manifestations; the recognition and proper management of these may improve patient outcomes.

Characteristics of Takotsubo cardiomyopathy in patients with COVID-19: Systematic scoping review

“…Reviews, opinion articles, studies that diagnosed COVID-19 without confirmatory PCR testing, a case with significant coronary artery disease, and irrelevant topics were excluded. 40 articles with 52 cases were included in our review [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] .

Fig.

…”

Nanomedicine, Viral Infection and Cytokine Stor

“…These features are underlined as major causes which were identified in the later stages of the disease, are responsible for the death or increase its rate. These nanoscale tools and devices can easily identify SARS-CoV-2 via smart and innovative nanobased in-built technologies [21]. It is concluded here that these multifunctional bioengineered nanomaterials can be useful in the detection, prevention, and treatment of viral infections.…”

Heart failure during the COVID‐19 pandemic: clinical, diagnostic, management, and organizational dilemmas

“…Only few cases have been described as fulminant myocarditis leading to CS in the recovery period. 68,98 HF aggravates clinical course of COVID infection as it could impair respiratory and systemic conditions. 99 Heart failure with preserved ejection fraction Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome including a broad population with different pathophysiological triggers, CV risk, and demographic features, resulting in large a spectrum of different phenotypes.…”

“…The myocardial inflammation is probably transient and proceeds to complete recovery within few weeks. Only few cases have been described as fulminant myocarditis leading to CS in the recovery period 68,98 . HF aggravates clinical course of COVID infection as it could impair respiratory and systemic conditions 99 …”